Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.22
HOLX's Cash to Debt is ranked lower than
82% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.21 vs. HOLX: 0.22 )
Ranked among companies with meaningful Cash to Debt only.
HOLX' s 10-Year Cash to Debt Range
Min: 0.04  Med: 1.09 Max: No Debt
Current: 0.22
Equity to Asset 0.28
HOLX's Equity to Asset is ranked lower than
86% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.60 vs. HOLX: 0.28 )
Ranked among companies with meaningful Equity to Asset only.
HOLX' s 10-Year Equity to Asset Range
Min: 0.22  Med: 0.68 Max: 0.88
Current: 0.28
0.22
0.88
Interest Coverage 1.27
HOLX's Interest Coverage is ranked lower than
93% of the 111 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 53.79 vs. HOLX: 1.27 )
Ranked among companies with meaningful Interest Coverage only.
HOLX' s 10-Year Interest Coverage Range
Min: 0.55  Med: 63.25 Max: 9999.99
Current: 1.27
0.55
9999.99
F-Score: 7
Z-Score: 1.09
M-Score: -2.83
WACC vs ROIC
7.83%
5.36%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 15.82
HOLX's Operating margin (%) is ranked higher than
79% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.48 vs. HOLX: 15.82 )
Ranked among companies with meaningful Operating margin (%) only.
HOLX' s 10-Year Operating margin (%) Range
Min: -123.18  Med: 5.59 Max: 20.99
Current: 15.82
-123.18
20.99
Net-margin (%) 5.05
HOLX's Net-margin (%) is ranked higher than
57% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.54 vs. HOLX: 5.05 )
Ranked among companies with meaningful Net-margin (%) only.
HOLX' s 10-Year Net-margin (%) Range
Min: -135.4  Med: 1.05 Max: 16.59
Current: 5.05
-135.4
16.59
ROE (%) 6.34
HOLX's ROE (%) is ranked higher than
53% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.29 vs. HOLX: 6.34 )
Ranked among companies with meaningful ROE (%) only.
HOLX' s 10-Year ROE (%) Range
Min: -60.17  Med: 0.86 Max: 17.54
Current: 6.34
-60.17
17.54
ROA (%) 1.64
HOLX's ROA (%) is ranked lower than
52% of the 193 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.43 vs. HOLX: 1.64 )
Ranked among companies with meaningful ROA (%) only.
HOLX' s 10-Year ROA (%) Range
Min: -32.08  Med: 0.20 Max: 14.52
Current: 1.64
-32.08
14.52
ROC (Joel Greenblatt) (%) 52.92
HOLX's ROC (Joel Greenblatt) (%) is ranked higher than
86% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.56 vs. HOLX: 52.92 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
HOLX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -369.68  Med: 12.67 Max: 90.76
Current: 52.92
-369.68
90.76
Revenue Growth (3Y)(%) 10.30
HOLX's Revenue Growth (3Y)(%) is ranked higher than
76% of the 151 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. HOLX: 10.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
HOLX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -7.7  Med: 10.30 Max: 35.9
Current: 10.3
-7.7
35.9
EBITDA Growth (3Y)(%) 5.00
HOLX's EBITDA Growth (3Y)(%) is ranked lower than
53% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.70 vs. HOLX: 5.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
HOLX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -5.1  Med: 35.75 Max: 90.5
Current: 5
-5.1
90.5
EPS Growth (3Y)(%) -53.30
HOLX's EPS Growth (3Y)(%) is ranked lower than
98% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.70 vs. HOLX: -53.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
HOLX' s 10-Year EPS Growth (3Y)(%) Range
Min: -68.1  Med: 79.00 Max: 369.3
Current: -53.3
-68.1
369.3
» HOLX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

HOLX Guru Trades in Q4 2014

Jim Simons 2,260,618 sh (+43.60%)
Vanguard Health Care Fund 7,379,300 sh (unchged)
Carl Icahn 34,154,879 sh (unchged)
Prem Watsa 20,000 sh (unchged)
Joel Greenblatt Sold Out
Ken Fisher 128,300 sh (-1.07%)
Murray Stahl 31,389 sh (-7.17%)
Kahn Brothers 1,420,442 sh (-7.83%)
Paul Tudor Jones 29,530 sh (-95.53%)
» More
Q1 2015

HOLX Guru Trades in Q1 2015

Ken Fisher 128,300 sh (unchged)
Vanguard Health Care Fund 7,379,300 sh (unchged)
Prem Watsa 20,000 sh (unchged)
Carl Icahn 34,154,879 sh (unchged)
Kahn Brothers 1,377,802 sh (-3.00%)
Murray Stahl 26,148 sh (-16.70%)
Paul Tudor Jones 20,037 sh (-32.15%)
Jim Simons 1,501,318 sh (-33.59%)
» More
Q2 2015

HOLX Guru Trades in Q2 2015

RS Investment Management 549,790 sh (New)
RS Investment Management 549,790 sh (New)
Vanguard Health Care Fund 7,379,300 sh (unchged)
Prem Watsa 20,000 sh (unchged)
Ken Fisher 128,300 sh (unchged)
Carl Icahn 34,154,879 sh (unchged)
Paul Tudor Jones Sold Out
Kahn Brothers 1,359,812 sh (-1.31%)
Murray Stahl 24,370 sh (-6.80%)
Jim Simons 174,400 sh (-88.38%)
» More
2015

HOLX Guru Trades in 2015

Carl Icahn 28,154,879 sh (-17.57%)
» More
» Details

Insider Trades

Latest Guru Trades with HOLX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 85.10
HOLX's P/E(ttm) is ranked lower than
90% of the 113 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.00 vs. HOLX: 85.10 )
Ranked among companies with meaningful P/E(ttm) only.
HOLX' s 10-Year P/E(ttm) Range
Min: 25.24  Med: 57.09 Max: 470.18
Current: 85.1
25.24
470.18
Forward P/E 22.03
HOLX's Forward P/E is ranked lower than
51% of the 75 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.74 vs. HOLX: 22.03 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 84.60
HOLX's PE(NRI) is ranked lower than
91% of the 112 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.40 vs. HOLX: 84.60 )
Ranked among companies with meaningful PE(NRI) only.
HOLX' s 10-Year PE(NRI) Range
Min: 25.41  Med: 56.99 Max: 446.67
Current: 84.6
25.41
446.67
P/B 5.00
HOLX's P/B is ranked lower than
74% of the 178 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.91 vs. HOLX: 5.00 )
Ranked among companies with meaningful P/B only.
HOLX' s 10-Year P/B Range
Min: 0.59  Med: 2.01 Max: 9.8
Current: 5
0.59
9.8
P/S 4.30
HOLX's P/S is ranked lower than
63% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.67 vs. HOLX: 4.30 )
Ranked among companies with meaningful P/S only.
HOLX' s 10-Year P/S Range
Min: 1.47  Med: 2.84 Max: 7.73
Current: 4.3
1.47
7.73
PFCF 18.93
HOLX's PFCF is ranked higher than
80% of the 83 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.56 vs. HOLX: 18.93 )
Ranked among companies with meaningful PFCF only.
HOLX' s 10-Year PFCF Range
Min: 6.51  Med: 17.09 Max: 2932
Current: 18.93
6.51
2932
POCF 16.71
HOLX's POCF is ranked higher than
57% of the 114 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.43 vs. HOLX: 16.71 )
Ranked among companies with meaningful POCF only.
HOLX' s 10-Year POCF Range
Min: 5.48  Med: 14.46 Max: 124.63
Current: 16.71
5.48
124.63
EV-to-EBIT 35.92
HOLX's EV-to-EBIT is ranked lower than
78% of the 120 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.58 vs. HOLX: 35.92 )
Ranked among companies with meaningful EV-to-EBIT only.
HOLX' s 10-Year EV-to-EBIT Range
Min: -125.3  Med: 29.20 Max: 118
Current: 35.92
-125.3
118
Current Ratio 1.37
HOLX's Current Ratio is ranked lower than
80% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.41 vs. HOLX: 1.37 )
Ranked among companies with meaningful Current Ratio only.
HOLX' s 10-Year Current Ratio Range
Min: 1.07  Med: 2.76 Max: 7.31
Current: 1.37
1.07
7.31
Quick Ratio 1.12
HOLX's Quick Ratio is ranked lower than
69% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.60 vs. HOLX: 1.12 )
Ranked among companies with meaningful Quick Ratio only.
HOLX' s 10-Year Quick Ratio Range
Min: 0.85  Med: 2.18 Max: 6.57
Current: 1.12
0.85
6.57
Days Inventory 90.28
HOLX's Days Inventory is ranked higher than
74% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 128.59 vs. HOLX: 90.28 )
Ranked among companies with meaningful Days Inventory only.
HOLX' s 10-Year Days Inventory Range
Min: 65.34  Med: 93.57 Max: 159.78
Current: 90.28
65.34
159.78
Days Sales Outstanding 52.47
HOLX's Days Sales Outstanding is ranked higher than
68% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 63.01 vs. HOLX: 52.47 )
Ranked among companies with meaningful Days Sales Outstanding only.
HOLX' s 10-Year Days Sales Outstanding Range
Min: 57.11  Med: 76.60 Max: 195.7
Current: 52.47
57.11
195.7

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.81
HOLX's Price/Projected FCF is ranked lower than
53% of the 95 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.76 vs. HOLX: 1.81 )
Ranked among companies with meaningful Price/Projected FCF only.
HOLX' s 10-Year Price/Projected FCF Range
Min: 0.41  Med: 1.21 Max: 12.14
Current: 1.81
0.41
12.14
Price/Median PS Value 1.53
HOLX's Price/Median PS Value is ranked lower than
75% of the 166 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.15 vs. HOLX: 1.53 )
Ranked among companies with meaningful Price/Median PS Value only.
HOLX' s 10-Year Price/Median PS Value Range
Min: 0.16  Med: 0.89 Max: 2.67
Current: 1.53
0.16
2.67
Earnings Yield (Greenblatt) (%) 2.80
HOLX's Earnings Yield (Greenblatt) (%) is ranked lower than
51% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. HOLX: 2.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
HOLX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.8  Med: 2.80 Max: 7.9
Current: 2.8
0.8
7.9
Forward Rate of Return (Yacktman) (%) 19.73
HOLX's Forward Rate of Return (Yacktman) (%) is ranked higher than
76% of the 92 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 12.13 vs. HOLX: 19.73 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
HOLX' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: -0.8  Med: 6.70 Max: 76.6
Current: 19.73
-0.8
76.6

Analyst Estimate

Sep15 Sep16 Sep17
Revenue(Mil) 2,692 2,816 2,952
EPS($) 1.65 1.80 1.99
EPS without NRI($) 1.65 1.80 1.99

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Traded in other countries:HO1.Germany,
Hologic Inc was incorporated in Massachusetts in October 1985 and reincorporated in Delaware in March 1990. The Company is a developer, manufacturer and supplier of medical imaging systems and diagnostic and surgical products focused on the healthcare needs of women. The Company's core business segments are focused on breast health, diagnostics, GYN surgical and skeletal health. The Company's breast health products include a broad portfolio of breast imaging and related products and accessories, including digital and film-based mammography systems, computer-aided detection (CAD), minimally invasive breast biopsy and tissue extraction devices, breast biopsy guidance systems, breast imaging comfort pads, and breast brachytherapy products. It has also developed a new breast imaging platform, Dimensions, which utilizes a new technology, tomosynthesis, to produce 3D images. The Company's diagnostic product offerings include the ThinPrep System used mainly for cytology applications, such as cervical cancer screening, and the Rapid Fetal Fibronectin Test for pre-term birth risk assessment. The Company's surgical product offerings include the NovaSure System, and the Adiana System. The NovaSure System enables physicians to treat women suffering from excessive menstrual bleeding in a minimally invasive manner. The Adiana System is a form of permanent female contraception intended as an alternative to tubal ligation. It sells and services its products through a combination of direct sales and service forces and a network of independent distributors and sales representatives. The Company's mammography and related products and subsystems compete with products offered by a number of competitors, including GE, Siemens, Philips, PlanMed, Agfa, Carestream Health, Fuji, IMS Giotto, Sectra and Toshiba. The manufacture, sale, lease and service of medical diagnostic and surgical devices and pharmaceutical products intended for commercial use are subject to extensive governmental regulation by the FDA in the United States and by a variety of regulatory agencies in other countries.
» More Articles for HOLX

Headlines

Articles On GuruFocus.com
Weekly 52-Week Highs Highlight: STI, GS, HOLX, MHK Jun 09 2015 
Reversing a Declining Pattern in Earnings Per Share Feb 24 2015 
Carl Icahn Letter On His Standstill Agreement With Ebay Jan 22 2015 
actionview Dec 06 2014 
Hologic Produces the First FDA-Approved 3D Mammography Platform Nov 26 2014 
Paul Tudor Jones Lives Up to Reputation As Active Trader in Third Quarter Nov 24 2014 
No More a Simple Distributor Sep 07 2014 
Carl Icahn Bets on Hologic; Should You? Aug 19 2014 
Weekly CFO Sells Highlight: Travelers Companies, Facebook, Hologic May 12 2014 
Weekly CEO Buys Highlight: HOLX, EPB, CLMS, IDTI, BYI Feb 17 2014 

More From Other Websites
HOLOGIC INC Files SEC form 8-K, Change in Directors or Principal Officers Aug 24 2015
Hologic (HOLX) Grows Overseas, Shifts Strategy to Drive Growth Aug 24 2015
Breast health stock on a tear Aug 13 2015
Billionaire Carl Icahn Trims Stake in Hologic Inc. (HOLX) but Still Likes the Company Aug 05 2015
Hologic to Present at Upcoming Investor Conferences Aug 04 2015
HOLOGIC INC Financials Aug 04 2015
Hologic (HOLX) Looks Good: Stock Moves 7.2% Higher - Tale of the Tape Jul 31 2015
UBS Leads More Banking Stocks To New Highs Jul 30 2015
Hologic Outshines Q3 Earnings and Revenues; FY15 View Up - Analyst Blog Jul 30 2015
Edited Transcript of HOLX earnings conference call or presentation 29-Jul-15 8:30pm GMT Jul 29 2015
Hologic shares climb on 3Q results and boost to outlook Jul 29 2015
Hologic shares climb on 3Q results and boost to outlook Jul 29 2015
Hologic beats Street 3Q forecasts Jul 29 2015
Hologic beats Street 3Q forecasts Jul 29 2015
Hologic Inc Earnings Call scheduled for 4:30 pm ET today Jul 29 2015
HOLOGIC INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Jul 29 2015
Hologic Announces Financial Results for Third Quarter of Fiscal 2015 Jul 29 2015
Intuitive Surgical, Inc. Earnings Analysis: By the Numbers Jul 27 2015
Coverage initiated on Hologic by BofA/Merrill Jul 24 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK